Back to Authors

Dhruva, Sanket S.

https://orcid.org/0000-0003-0674-2032

Mayo Clinic

San Francisco VA Medical Center

Citations 28

Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017
Bartlett, Victoria , Liu, Patrick , Dhruva, Sanket S. , Shah, Nilay D. , Bollinger, Kathryn , Ross, Joseph S. , Ross, Joseph S

Journal of Managed Care & Specialty Pharmacy | March 30, 2020 | Volume: 26 | Issue: 4 | Pages: 562-567

10.18553/jmcp.2020.26.4.562 Get It

Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock
Dhruva, Sanket S. , Ross, Joseph S. , Hurley, Nathan C. , Curtis, Jeptha P. , Berkowitz, Alyssa, Masoudi, Frederick A. , Messenger, John C. , Parzynski, Craig S. , Girotra, Saket , Amin, Amit P. , Shah, Nilay D. , Ross, Joseph S , Mortazavi, Bobak J. , Krumholz, Harlan M. , Ngufor, Che , Desai, Nihar R.

JAMA | February 10, 2020 | Volume: 323 | Issue: 8 | Pages: 734

10.1001/jama.2020.0254 Get It

Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings
Solotke, Michael T. , Ross, Joseph S. , Shah, Nilay D. , Karaca‐Mandic, Pinar , Dhruva, Sanket S. , Ross, Joseph S

Journal of Managed Care & Specialty Pharmacy | October 30, 2019 | Volume: 25 | Issue: 11 | Pages: 1201-1217

10.18553/jmcp.2019.25.11.1201 Get It

Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence
Bartlett, Victoria , Dhruva, Sanket S. , Shah, Nilay D. , Ryan, Patrick , Ross, Joseph S. , Ross, Joseph S

JAMA Network Open | October 9, 2019 | Volume: 2 | Issue: 10 | Pages: e1912869

10.1001/jamanetworkopen.2019.12869 Get It

Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates
Dayoub, Elias J. , Ross, Joseph S. , Shah, Nilay D. , Dhruva, Sanket S. , Ross, Joseph S

Circulation | September 30, 2019 | Volume: 140 | Issue: 14 | Pages: 1227-1230

10.1161/circulationaha.119.040580 Get It

Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10‐Year Assessment
DuBose‐Briski, Victoria, Dhruva, Sanket S. , Ross, Joseph S. , Shah, Nilay D. , Yao, Xiaoxi , Dunlay, Shannon M. , Ross, Joseph S , Kalinoski-DuBose, Victoria , Noseworthy, Peter A.

Journal of the American Heart Association | September 28, 2019 | Volume: 8 | Issue: 19 | Pages: No page available

10.1161/jaha.119.012065 Get It

Background The American College of Cardiology and American Heart Association periodically revise clinical practice guidelines. We evaluated changes in the evidence underlying guidelines published over a 10‐year period. Methods and Results Thirty‐five American College of Cardiology/American Heart Association guidelines were divided into 2 time periods: 2008 to 2012 and 2013 to 2017. Guidelines were categorized into the following topic areas: arrhythmias, prevention, acute and stable ischemia, heart failure, valvular heart disease, and vascular medicine. Changes in recommendations were assessed for each topic area. American College of Cardiology/American Heart Association designated class of recommendation as level I, II , or III (I represented “strongly recommended”) and levels of evidence ( LOE ) as A, C, or C (A represented “highest quality”). The median number of recommendations per each topic area was 281 (198–536, interquartile range) in 2008 to 2012 versus 247 (190–451.3, interquartile range) in 2013 to 2017. The median proportion of class of recommendation I was 49.3% and 44.4% in the 2 time periods, 38.0% and 44.5% for class of recommendation II , and 12.5% and 11.2% for class of recommendation III . Median proportions for LOE A were 15.7% and 14.1%, 41.0% and 52.8% for LOE B, and 46.9% and 32.5% for LOE C. The decrease in the proportion of LOE C was highest in heart failure (24.8%), valvular heart disease (22.3%), and arrhythmia (19.2%). An increase in the proportion of LOE B was observed for these same areas: 31.8%, 23.8%, and 19.2%, respectively. Conclusions There has been a decrease in American College of Cardiology/American Heart Association guidelines recommendations, driven by removal of recommendations based on lower quality of evidence, although there was no corresponding increase in the highest quality of evidence.
Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs
Liu, Patrick , Dhruva, Sanket S. , Shah, Nilay D. , Ross, Joseph S. , Ross, Joseph S

Annals of Internal Medicine | July 24, 2018 | Volume: 169 | Issue: 11 | Pages: 817-819

10.7326/m18-0965 Get It

New and incremental FDA black box warnings from 2008 to 2015
Solotke, Michael T. , Dhruva, Sanket S. , Downing, Nicholas S., Shah, Nilay D. , Ross, Joseph S. , Ross, Joseph S

Expert Opinion on Drug Safety | December 7, 2017 | Volume: 17 | Issue: 2 | Pages: 117-123

10.1080/14740338.2018.1415323 Get It